TrialJapanese journal of clinical oncology2023

Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial.

Hiroji Iwata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.